EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Proteomic profiling links complement activation to thrombosis in JAK2V617F myeloproliferative neoplasms

Blanca De Moner, Julia Martinez-Sanchez, Silvia Escribano-Serrat, Alex Ramos, Ana Belén Moreno-Castaño, Eduardo Arellano-Rodrigo, Ginés Escolar, Enric Carreras, Alberto Álvarez-Larrán, Maribel Diaz-Ricart

Translational Oncology · 2025-12 · 62 · 102561

DOI: 10.1016/j.tranon.2025.102561 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Oncology, 2025-12. Verfasst von Blanca De Moner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hemostasis and Erythropathology laboratory, Hematopathology, Pathology Department, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic de Barcelona,…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Government of Catalonia Agency for Administration of University and Research Grants, Carlos III Health Institute, Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Myeloproliferative neoplasms (MPNs) are associated with a high risk of thrombotic complications, particularly splanchnic vein thrombosis (SVT). This study aimed to elucidate the proteomic signature of JAK2V617F-mutated MPN patients with and without SVT, focusing on dysregulated pathways contributing to thrombotic risk. METHODS: We conducted a comprehensive proteomic analysis of plasma samples from 28 JAK2V617F-mutated MPN patients (22 with SVT, 6 without thrombosis) and 6 healthy controls. Proteins were quantified using TMT labeling and nanoLC-MS/MS, followed by multivariate and univariate statistical analyses. FINDINGS: A total of 275 high-confidence proteins were identified. Compared to controls, MPN patients exhibited significant dysregulation of complement and coagulation pathways, with upregulation of complement components (C1QA, C1QB, C1QC, C7) and endothelial adhesion molecules (VCAM1, ICAM1), along with downregulation of anticoagulant proteins (PROS1, SERPINA10). SVT patients showed heightened complement activation, markedly increased C7, VCAM1, and von Willebrand factor, and reduced levels of coagulation factors (F9, F10, F11). Hierarchical clustering and pathway enrichment analyses highlighted the central role of complement activation, platelet activation, and endothelial dysfunction in SVT pathogenesis. Serum validation confirmed elevated alternative pathway markers (Ba, Bb) and terminal complement products (C5a, sC5b-9) in SVT, implicating complement activation as a key driver of thrombosis. INTERPRETATION: This study identifies complement activation as a potential key contributor to thrombosis in JAK2V617F MPN patients, particularly those with SVT. The interplay between complement, coagulation, and endothelial dysfunction suggests potential therapeutic targets for reducing thrombotic complications in this high-risk population. FUNDING: This work was supported by AGAUR, ISCIII, and Novartis.

Schlagwörter

Stichwörter der Autor:innen

Complement systemEndotheliumMyeloproliferative neoplasmsProteomicsSplanchnic vein thrombosis

Autor:innen und Institutionen

  • Hemostasis and Erythropathology laboratory, Hematopathology, Pathology Department, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), U…
  • Hematology Department, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain. Electronic address: arellano@clinic.cat.
  • Josep Carreras Leukaemia Research Institute, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain; Barcelona Endothelium Team, Barcelona, Spain.
  • Hematology Department, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.

Förderung

  • Government of Catalonia Agency for Administration of University and Research Grants
  • Carlos III Health Institute
  • Novartis
  • Universitat Rovira i Virgili
  • Departament de Recerca i Universitats, Generalitat de Catalunya
  • Novartis Pharmaceuticals

Zitieren

APA

De Moner, B., Martinez-Sanchez, J., Escribano-Serrat, S., Ramos, A., Moreno-Castaño, A. B., Arellano-Rodrigo, E., Escolar, G., Carreras, E., Álvarez-Larrán, A., & Diaz-Ricart, M. (2025). Proteomic profiling links complement activation to thrombosis in JAK2V617F myeloproliferative neoplasms. Translational Oncology, 62, 102561. https://doi.org/10.1016/j.tranon.2025.102561

Vancouver

De Moner B, Martinez-Sanchez J, Escribano-Serrat S, Ramos A, Moreno-Castaño AB, Arellano-Rodrigo E, et al. Proteomic profiling links complement activation to thrombosis in JAK2V617F myeloproliferative neoplasms. Translational Oncology. 2025;62:102561. doi:10.1016/j.tranon.2025.102561

BibTeX
@article{DeMoner2025,
  author = {De Moner, Blanca and Martinez-Sanchez, Julia and Escribano-Serrat, Silvia and Ramos, Alex and Moreno-Castaño, Ana Belén and Arellano-Rodrigo, Eduardo and Escolar, Ginés and Carreras, Enric and Álvarez-Larrán, Alberto and Diaz-Ricart, Maribel},
  title = {Proteomic profiling links complement activation to thrombosis in JAK2V617F myeloproliferative neoplasms},
  journal = {Translational Oncology},
  year = {2025},
  volume = {62},
  pages = {102561},
  doi = {10.1016/j.tranon.2025.102561}
}
Kostenlos starten →